3Helix is based in Salt Lake City, Utah. It was founded by Drs. Yang Li and Michael Yu based on the technology that they invented at the Johns Hopkins University.
Damage to collagen, the major component of nearly every human tissue, is a strong indication of connective tissue injury, as well as a variety of diseases. However, targeting damaged collagen is difficult with conventional technologies.
3Helix has developed a series of proprietary collagen hybridizing peptides (CHP) that directly target the damaged collagen molecule.
Applications for CHPs: